Basilea Pharmaceutica AG
BPMUF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -21.4% | 73.3% | 4.9% | – |
| Cost of Goods Sold | $0 | -$0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 39.9% | 109.9% | 32.2% | 76.9% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | -$0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | $0 | $0 | -$0 |
| % Margin | 23.1% | 39.3% | 12.1% | -24.3% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | -$0 |
| Pre-Tax Income | $0 | $0 | $0 | -$0 |
| Tax Expense | $0 | -$0 | -$0 | -$0 |
| Net Income | $0 | $0 | $0 | -$0 |
| % Margin | 15.2% | 43% | 27.2% | -29.4% |
| EPS | 1.29 | 4.7 | 1.61 | -1.78 |
| % Growth | -72.6% | 191.9% | 190.4% | – |
| EPS Diluted | 1.26 | 4.2 | 1.5 | -1.78 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | -$0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 24.1% | 42.5% | 13.3% | 4.3% |